Chairman, Chief Executive Officer
Mr. Hensley has years of management experience in the scientific and analytical instrument industry. During his career before inventing IonField’s plasma process, he worked for Beckman Instruments (pre-GSK & Danaher) and Zymark (pre-Caliper and PE). Besides IonField, Mr. Hensley is a serial entrepreneur, founding Cardinal Instruments and Cerionx.
In 2000, he filed the original patent on the use of plasma to clean pipet tips and microplates, and formed Cerionx. In 2009, IonField acquired exclusive rights to the patents and the designs of the TipCharger product.
Mr. Hensley is a graduate of Haverford College and attended graduate school at Thomas Jefferson University.
In his personal life, Mr. Hensley is active in the international sports community, president of a non-profit sports organization based at Haverford College and an avid cyclist.
Board of Directors
Baiada is managing partner at BaseCamp Ventures an early stage venture fund; president of Basecamp Business; and a partner of Grapevine Development a smart-growth NJ based real estate development firm. Operating and investing in successful product and service-based companies has given him a broad and seasoned perspective of business.
From the start-up of Bluestone in 1989, through its IPO in 1999, and the eventual sale to Hewlett Packard in 2001 for over $350M, Mel has demonstrated an ability to recognize business opportunities, attract capital and talented employees, and profitability exit an information technology company investment.
Mel has made a number of contributions to the Greater Delaware Valley area to promote technological growth in the community. As an alumnus of Drexel University, Mel has made a generous donation to Drexel University for the establishment of The Laurence A. Baiada Institute for Entrepreneurship in Technology. He is the recipient of the Greater Philadelphia Venture Group “Year 2000 Entrepreneur of the Year” Award. In addition, Mel was recognized in 2001 by the New Jersey Technology Council with its “High Tech Hero Award” and an Ernst & Young, Entrepreneur of the Year finalist.
Mel’s road to success began when he founded Bluestone, Inc. in 1989 to provide information technology expertise to Fortune 1000 companies. Bluestone rapidly grew to a multi-million dollar company, earning Bluestone inclusion in the Inc. 500 list of the fastest growing privately held companies in the U.S. for three straight years, from 1994 to 1996. Bluestone was also a member of the Philadelphia 100 for five consecutive years earning a place in the Philadelphia 100 Hall of Fame. In 1997, Bluestone split into two separate entities, Bluestone Software, Inc. and Bluestone Consulting, Inc. Bluestone Software accomplished a successful IPO in 1999 and has achieved industry recognition in the Web application server marketplace. In 2001, Hewlett Packard acquired Bluestone Software.
In 2000, the IT and Internet services division of Bluestone Consulting, Inc. began “Doing Business As”, Sengen, that specialized in streamlining business processes through the use of technology. Sengen was sold in December of 2003.
Mel serves on the boards of Drexel University, New Jersey Technology Council (former board chair), Bayada Home Health Care and several boards of Basecamp Ventures portfolio companies. Former Boards that Mel has served on have included Moorestown Friends School, Innovation Philadelphia and South Jersey Technology Park at Rowan University.
Mel has two children and lives with his wife in Moorestown, New Jersey.
F. Raymond Salemme, PhD
Ray Salemme is a scientist-entrepreneur with over 30 years experience in academia, biotechnology, and pharmaceutical drug discovery. Over the years he has built and directed multidisciplinary scientific groups at Genex, DuPont Central Research, DuPont Merck Pharmaceuticals, and Sterling Winthrop Pharmaceuticals. Originally trained as a protein X-ray crystallographer, he has been a pioneer in the development of structure-based, biophysical, and computational methods for drug discovery.
In 1993 he founded 3-Dimensional Pharmaceuticals, a biotechnology company that integrated structure-based drug design and combinatorial chemistry using a comprehensive computational framework for discovery process control. 3DP went public on NASDAQ in 2000, and was ultimately acquired by Johnson & Johnson in 2003. Subsequently Dr. Salemme served as CEO and built the discovery platform at Redpoint Bio, a company developing compounds that modulate chemoreceptors for nutritional applications and diabetes control. He currently serves as CEO of Imiplex LLC, a company he founded for the development of engineered proteins for nanotechnology applications.
Dr. Salemme is co-inventor on 39 Issued US Patents, including computational methods for drug discovery, engineered protein compositions of matter, and methods and instrumentation for high throughput screening and protein characterization using thermodynamic methods. Dr. Salemme holds a BA in Molecular Biophysics from Yale University and a PhD in Chemistry (Protein Crystallography) from UCSD.